Expanded Access to Adagrasib (MRTX849) for Patients with Advanced Solid Tumors with KRAS G12C Mutation
Sponsor: Mirati Therapeutics Inc.
Expanded Access
Approved for Marketing
Sponsor score: 40
ClinicalTrials ID:NCT05162443
This program offers access to the drug adagrasib (MRTX849) for patients with advanced solid tumors that have a specific genetic mutation called KRAS G12C, who have already received treatment and have limited options.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this program is to provide access to the drug adagrasib (MRTX849) for patients with advanced solid tumors that have a KRAS G12C mutation. This is for patients who have already been treated but need more options because they cannot join a clinical trial or receive standard treatments.
Eligibility Criteria
Inclusion Criteria
- Have a confirmed diagnosis of an advanced or metastatic solid tumor.
- Have a confirmed KRAS G12C mutation in the tumor.
- Cannot join a current clinical trial for MRTX849.
- No other standard treatment options available or not eligible for them.
- Have good organ function.
- Can have cancer that has spread to the brain, under certain conditions.
- Have an ECOG performance status of 2 or less, meaning they are able to carry out light work or are fully active.
Exclusion Criteria
- Have a history of intestinal diseases or surgeries that affect digestion or the ability to swallow.
- Have had previous treatments targeting the KRAS G12C mutation.
- Have another active cancer.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| California Pacific Medical Center | 94115 | San Francisco | California |
| Providence Medical Group Santa Rosa - Cancer Center | 95403 | Santa Rosa | California |
| Hartford Hospital | 06106 | Hartford | Connecticut |
| Piedmont Cancer Institute | 30318 | Atlanta | Georgia |
| Mayo Clinic - Rochester | 55905 | Rochester | Minnesota |
| Renown Health | 89502 | Reno | Nevada |
| Lehigh Valley Cancer Institute | 18103 | Allentown | Pennsylvania |
| Lumi Research | 77339 | Kingwood | Texas |
| Virginia Cancer Institute | 23230 | Richmond | Virginia |
| Seattle Integrative Cancer Center | 98057 | Renton | Washington |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.